Contact Us

Following an extensive review, and in light of increasing costs to maintain compliance with regulatory requirements, EmeraMed can no longer afford to support patients through its Early Access Program, sometimes referred to as Compassionate Use, Expanded Access, Name Patient Use or Single Patient IND programs. The Board of EmeraMed has therefore regretfully decided to discontinue the program worldwide until further notice. This decision is not related to any efficacy or safety concerns: there has never been a Serious Adverse Event arising from this program or from any of the multiple clinical trials conducted to date using Emeramide or Irminix. We remain committed to bring Emeramide to market as quickly as possible.